August 12, 2022 Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies C-Path’s Type 1 Diabetes Consortium (T1DC) is pleased to announce that “Consortium-based approach to receiving an EMA...
July 19, 2022 Comparing patient global impression of severity and patient global impression of change to evaluate test–retest reliability of depression, non-small cell lung cancer, and asthma measures
June 8, 2022 Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): measurement properties and estimated clinically meaningful thresholds from a phase 3 study
May 16, 2022 Recommendations for the Electronic Migration and Implementation of Clinician-Reported Outcome Assessments in Clinical Trials
April 26, 2022 C-Path in Europe: Moving Global Regulatory Science Forward Critical Path Institute is a catalyst for innovation that accelerates the path to a healthier world...
April 11, 2022 Quantitative System Pharmacology as a Legitimate Approach to Examine Extrapolation Strategies used to Support Pediatric Drug Development; Azer K, Barrett JS
April 11, 2022 Role of Disease Progression Models in Drug Development. Pharmaceutical Research; Jeffrey S Barrett, Tim Nicholas, Karim Azer, Brian W Corrigan
